English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#advancedhcc search results

MountSinaiLiver's profile picture. Official account of the Division of Liver Diseases @MountSinaiNYC
MountSinaiLiver
 @MountSinaiLiver
May 7, 2022

Poster highlights #AACRliver22 immune cell & checkpoint ligand expression in immunotherapy #advancedhcc @IcahnMountSinai @AACR @CappuynsSarah

MountSinaiLiver's tweet image. Poster highlights #AACRliver22 immune cell & checkpoint ligand expression in immunotherapy #advancedhcc @IcahnMountSinai @AACR @CappuynsSarah
0
4
27
0
0
PerelloChristie's profile picture. Gastroenterología-Hepatología. Liver Unit, Hospital Universitario Puerta de Hierro.
Christie Perelló
 @PerelloChristie
Apr 13, 2019

Dr @ma5RN explain who is the optimal candidate to sistemic therapy. #AdvancedHCC #IlC2019

PerelloChristie's tweet image. Dr @ma5RN explain who is the optimal candidate to sistemic therapy. #AdvancedHCC #IlC2019
0
1
8
0
0
CappuynsSarah's profile picture. MD PhD researcher in digestive oncology @UZLeuven and @Onco_KULeuven. FWO PhD fellow strategic basic research. Visiting researcher @MountSinaiLiver and @IDIBAPS
Sarah Cappuyns
 @CappuynsSarah
Mar 24, 2021

@JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab

CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
0
2
8
0
0
DrAngelaLamarca's profile picture. HPB and NET Medical Oncologist at @Hospital_FJD. Chair of @myESMO Communication Commitee. Lead of @EORTC NET WG. @enscca SC. #BiliaryCancer #HCC #NET #PDAC
Angela Lamarca
 @DrAngelaLamarca
Sep 14, 2024

Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors

DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
0
9
16
7
2K
ILCAnews's profile picture. The International Liver Cancer Association (ILCA) is the only international organisation devoted to liver cancer for experts from all related disciplines.
ILCA
 @ILCAnews
Jan 19, 2022

What is the role for single agent TKI first-line? Join @ArndtVogel's session in our next webinar to find out! Register here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy

ILCAnews's tweet image. What is the role for single agent TKI first-line? Join @ArndtVogel's session in our next webinar to find out! Register here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy
0
2
3
0
0
ILCAnews's profile picture. The International Liver Cancer Association (ILCA) is the only international organisation devoted to liver cancer for experts from all related disciplines.
ILCA
 @ILCAnews
Jan 21, 2022

What is the future for combining checkpoint inhibitors and TKIs? @LorenzaRimassa's presentation will give you great insights on the topic. Register for this free webinar here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy

ILCAnews's tweet image. What is the future for combining checkpoint inhibitors and TKIs? @LorenzaRimassa's presentation will give you great insights on the topic. Register for this free webinar here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy
0
2
4
0
0
Virezzia's profile picture. Gastro y feliz hepatóloga 😍. Amo a mis 🐶🐶😺
Viridiana
 @Virezzia
Aug 11, 2022

Podemos los hepatólogos dar la terapia sistémica del CHC? A veces parece que no hablamos el mismo idioma con Onco #hepatocellularcarcinoma #advancedhcc #hepatologist #systemictherapy

0
0
0
0
0
MathurAmitK's profile picture. Transplant/HB Surgeon/Professor @MayoClinic | Interests: Transplant Practice, Research, Quality, Policy, Education | @nldac_asts | @UF @UMichSurgery Alum
Amit K. Mathur, MD MS FACS
@MathurAmitK
May 14, 2020

New findings for treatment of #advancedHCC - atezo-bev had somewhat better outcomes compared to sorafenib, and similar AEs. Big news in the care of #HCC

This post is unavailable.
0
0
4
0
0
mydocwire's profile picture. DocWire News delivers the most relevant medical news to over 1M HCPs daily.
DocWire News
 @mydocwire
Dec 22, 2023

Dr. Fatema Tashrifwala discusses her research on #TACE plus #camrelizumab for patients with #AdvancedHCC and details what information is still needed to confirm the combination's efficacy. Learn more: buff.ly/3RNdS1W

0
0
0
0
65
mydocwire's profile picture. DocWire News delivers the most relevant medical news to over 1M HCPs daily.
DocWire News
 @mydocwire
Dec 21, 2023

In a recent discussion, Richard Finn, MD, and Amit Mahipal, MD, (@Amitmahipal79) highlighted a new study on #lenvatinib following #immunotherapy for patients with #AdvancedHCC. Learn more: buff.ly/3uXjPjI

0
1
0
0
99
angelopirozzi3's profile picture. MD| Oncology Fellow 🩺 | Humanitas University and Mayo Clinic (Phoenix)| ESMO Ambassador| Interested in HBP cancers💊🔬| views are my own
Angelo Pirozzi
 @angelopirozzi3
Jul 28, 2022

Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death<3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/

angelopirozzi3's tweet image. Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death&amp;lt;3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/
angelopirozzi3's tweet image. Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death&amp;lt;3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/
0
1
2
0
0
CappuynsSarah's profile picture. MD PhD researcher in digestive oncology @UZLeuven and @Onco_KULeuven. FWO PhD fellow strategic basic research. Visiting researcher @MountSinaiLiver and @IDIBAPS
Sarah Cappuyns
 @CappuynsSarah
Jun 5, 2023

Looking forward to sharing some of our work on #biomarkers of response to #atezobev in #advancedHCC very soon... Check it out👇 and come and see me in Vienna! @EASLnews #livertwitter @JDekervel @mpiquegili @ef_roger @augustoNYC @LambrechtsDlab @JAbrilFo

EASLnews's profile picture. Let's unite Hepatology! Become a member today and discover your membership benefits. ____________ RT ≠ endorsement. We express no political views.
EASLnews
@EASLnews
Jun 5, 2023

📣Research Revelation! 🌟 Get ready to be inspired at #EASLCongress 2023! 🚀🔬 🔍 Search the programme to find out more about this oral abstract: OS-059- YI Register now: 👉 easlcongress.eu/reg @CappuynsSarah #livertwitter

0
3
14
0
4K
0
2
18
1
3K
DrAngelaLamarca's profile picture. HPB and NET Medical Oncologist at @Hospital_FJD. Chair of @myESMO Communication Commitee. Lead of @EORTC NET WG. @enscca SC. #BiliaryCancer #HCC #NET #PDAC
Angela Lamarca
 @DrAngelaLamarca
Sep 14, 2024

Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors

DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
0
9
16
7
2K
mydocwire's profile picture. DocWire News delivers the most relevant medical news to over 1M HCPs daily.
DocWire News
 @mydocwire
Dec 22, 2023

Dr. Fatema Tashrifwala discusses her research on #TACE plus #camrelizumab for patients with #AdvancedHCC and details what information is still needed to confirm the combination's efficacy. Learn more: buff.ly/3RNdS1W

0
0
0
0
65
mydocwire's profile picture. DocWire News delivers the most relevant medical news to over 1M HCPs daily.
DocWire News
 @mydocwire
Dec 21, 2023

In a recent discussion, Richard Finn, MD, and Amit Mahipal, MD, (@Amitmahipal79) highlighted a new study on #lenvatinib following #immunotherapy for patients with #AdvancedHCC. Learn more: buff.ly/3uXjPjI

0
1
0
0
99
CappuynsSarah's profile picture. MD PhD researcher in digestive oncology @UZLeuven and @Onco_KULeuven. FWO PhD fellow strategic basic research. Visiting researcher @MountSinaiLiver and @IDIBAPS
Sarah Cappuyns
 @CappuynsSarah
Jun 5, 2023

Looking forward to sharing some of our work on #biomarkers of response to #atezobev in #advancedHCC very soon... Check it out👇 and come and see me in Vienna! @EASLnews #livertwitter @JDekervel @mpiquegili @ef_roger @augustoNYC @LambrechtsDlab @JAbrilFo

EASLnews's profile picture. Let's unite Hepatology! Become a member today and discover your membership benefits. ____________ RT ≠ endorsement. We express no political views.
EASLnews
@EASLnews
Jun 5, 2023

📣Research Revelation! 🌟 Get ready to be inspired at #EASLCongress 2023! 🚀🔬 🔍 Search the programme to find out more about this oral abstract: OS-059- YI Register now: 👉 easlcongress.eu/reg @CappuynsSarah #livertwitter

0
3
14
0
4K
0
2
18
1
3K
Virezzia's profile picture. Gastro y feliz hepatóloga 😍. Amo a mis 🐶🐶😺
Viridiana
 @Virezzia
Aug 11, 2022

Podemos los hepatólogos dar la terapia sistémica del CHC? A veces parece que no hablamos el mismo idioma con Onco #hepatocellularcarcinoma #advancedhcc #hepatologist #systemictherapy

0
0
0
0
0
angelopirozzi3's profile picture. MD| Oncology Fellow 🩺 | Humanitas University and Mayo Clinic (Phoenix)| ESMO Ambassador| Interested in HBP cancers💊🔬| views are my own
Angelo Pirozzi
 @angelopirozzi3
Jul 28, 2022

Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death<3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/

angelopirozzi3's tweet image. Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death&amp;lt;3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/
angelopirozzi3's tweet image. Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death&amp;lt;3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/
0
1
2
0
0
MountSinaiLiver's profile picture. Official account of the Division of Liver Diseases @MountSinaiNYC
MountSinaiLiver
 @MountSinaiLiver
May 7, 2022

Poster highlights #AACRliver22 immune cell & checkpoint ligand expression in immunotherapy #advancedhcc @IcahnMountSinai @AACR @CappuynsSarah

MountSinaiLiver's tweet image. Poster highlights #AACRliver22 immune cell &amp;amp; checkpoint ligand expression in immunotherapy #advancedhcc @IcahnMountSinai @AACR @CappuynsSarah
0
4
27
0
0
ILCAnews's profile picture. The International Liver Cancer Association (ILCA) is the only international organisation devoted to liver cancer for experts from all related disciplines.
ILCA
 @ILCAnews
Jan 21, 2022

What is the future for combining checkpoint inhibitors and TKIs? @LorenzaRimassa's presentation will give you great insights on the topic. Register for this free webinar here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy

ILCAnews's tweet image. What is the future for combining checkpoint inhibitors and TKIs? @LorenzaRimassa&apos;s presentation will give you great insights on the topic. Register for this free webinar here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy
0
2
4
0
0
ILCAnews's profile picture. The International Liver Cancer Association (ILCA) is the only international organisation devoted to liver cancer for experts from all related disciplines.
ILCA
 @ILCAnews
Jan 19, 2022

What is the role for single agent TKI first-line? Join @ArndtVogel's session in our next webinar to find out! Register here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy

ILCAnews's tweet image. What is the role for single agent TKI first-line? Join @ArndtVogel&apos;s session in our next webinar to find out! Register here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy
0
2
3
0
0
CappuynsSarah's profile picture. MD PhD researcher in digestive oncology @UZLeuven and @Onco_KULeuven. FWO PhD fellow strategic basic research. Visiting researcher @MountSinaiLiver and @IDIBAPS
Sarah Cappuyns
 @CappuynsSarah
Mar 24, 2021

@JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab

CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
0
2
8
0
0
MathurAmitK's profile picture. Transplant/HB Surgeon/Professor @MayoClinic | Interests: Transplant Practice, Research, Quality, Policy, Education | @nldac_asts | @UF @UMichSurgery Alum
Amit K. Mathur, MD MS FACS
@MathurAmitK
May 14, 2020

New findings for treatment of #advancedHCC - atezo-bev had somewhat better outcomes compared to sorafenib, and similar AEs. Big news in the care of #HCC

This post is unavailable.
0
0
4
0
0
PerelloChristie's profile picture. Gastroenterología-Hepatología. Liver Unit, Hospital Universitario Puerta de Hierro.
Christie Perelló
 @PerelloChristie
Apr 13, 2019

Dr @ma5RN explain who is the optimal candidate to sistemic therapy. #AdvancedHCC #IlC2019

PerelloChristie's tweet image. Dr @ma5RN explain who is the optimal candidate to sistemic therapy. #AdvancedHCC #IlC2019
0
1
8
0
0
MountSinaiLiver's profile picture. Official account of the Division of Liver Diseases @MountSinaiNYC
MountSinaiLiver
 @MountSinaiLiver
May 7, 2022

Poster highlights #AACRliver22 immune cell & checkpoint ligand expression in immunotherapy #advancedhcc @IcahnMountSinai @AACR @CappuynsSarah

MountSinaiLiver's tweet image. Poster highlights #AACRliver22 immune cell &amp;amp; checkpoint ligand expression in immunotherapy #advancedhcc @IcahnMountSinai @AACR @CappuynsSarah
0
4
27
0
0
PerelloChristie's profile picture. Gastroenterología-Hepatología. Liver Unit, Hospital Universitario Puerta de Hierro.
Christie Perelló
 @PerelloChristie
Apr 13, 2019

Dr @ma5RN explain who is the optimal candidate to sistemic therapy. #AdvancedHCC #IlC2019

PerelloChristie's tweet image. Dr @ma5RN explain who is the optimal candidate to sistemic therapy. #AdvancedHCC #IlC2019
0
1
8
0
0
ILCAnews's profile picture. The International Liver Cancer Association (ILCA) is the only international organisation devoted to liver cancer for experts from all related disciplines.
ILCA
 @ILCAnews
Jan 19, 2022

What is the role for single agent TKI first-line? Join @ArndtVogel's session in our next webinar to find out! Register here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy

ILCAnews's tweet image. What is the role for single agent TKI first-line? Join @ArndtVogel&apos;s session in our next webinar to find out! Register here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy
0
2
3
0
0
ILCAnews's profile picture. The International Liver Cancer Association (ILCA) is the only international organisation devoted to liver cancer for experts from all related disciplines.
ILCA
 @ILCAnews
Jan 21, 2022

What is the future for combining checkpoint inhibitors and TKIs? @LorenzaRimassa's presentation will give you great insights on the topic. Register for this free webinar here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy

ILCAnews's tweet image. What is the future for combining checkpoint inhibitors and TKIs? @LorenzaRimassa&apos;s presentation will give you great insights on the topic. Register for this free webinar here: register.gotowebinar.com/register/21836… #livercancer #advancedhcc #systemictherapy
0
2
4
0
0
DrAngelaLamarca's profile picture. HPB and NET Medical Oncologist at @Hospital_FJD. Chair of @myESMO Communication Commitee. Lead of @EORTC NET WG. @enscca SC. #BiliaryCancer #HCC #NET #PDAC
Angela Lamarca
 @DrAngelaLamarca
Sep 14, 2024

Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors

DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
DrAngelaLamarca's tweet image. Two trials in #AdvancedHCC presented at #ESMO24 to note 1- DUBHE-H-308: Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy – moving to phase III 2- ALTN-AK105-III-02: Anlotinib plus penpulimab versus sorafenib - improved OS   @myesmo #ESMOAmbassadors
0
9
16
7
2K
CappuynsSarah's profile picture. MD PhD researcher in digestive oncology @UZLeuven and @Onco_KULeuven. FWO PhD fellow strategic basic research. Visiting researcher @MountSinaiLiver and @IDIBAPS
Sarah Cappuyns
 @CappuynsSarah
Mar 24, 2021

@JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab

CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
CappuynsSarah's tweet image. @JDekervel presenting our research project on #biomarkers in #advancedHCC at @BGDO! Exciting stuff coming soon... @Onco_KULeuven @UZLeuven @LambrechtsDlab
0
2
8
0
0
angelopirozzi3's profile picture. MD| Oncology Fellow 🩺 | Humanitas University and Mayo Clinic (Phoenix)| ESMO Ambassador| Interested in HBP cancers💊🔬| views are my own
Angelo Pirozzi
 @angelopirozzi3
Jul 28, 2022

Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death<3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/

angelopirozzi3's tweet image. Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death&amp;lt;3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/
angelopirozzi3's tweet image. Can we go beyond #BCLCstaging limitations⁉️ 🚨#Prognosticmodel for #advancedHCC to predict #earlydeath(death&amp;lt;3 months) 👉6603 pts with stage IV HCC 👉Good AUCs shown below👇 ✅️Wise tool to guide treatment allocation pubmed.ncbi.nlm.nih.gov/35854221/
0
1
2
0
0

Something went wrong.


Something went wrong.


United States Trends